RANBAXY LABORATORIES LTD.FROM VISION TO ACTION

CASE-7

About the company

1961 Incorporated as a Private Limited Company

1969 Ist blockbuster brand Calmpose launched in India

1973 IPO (Initial Public Offering) launched; attains Public Limited company status(listed in Feb 1974)

1983 A modern pharmaceutical plant at Dewas (Madhya Pradesh), India, goes on stream

1987Production starts at the modern API plant, Toansa (Punjab), India, making Ranbaxy, the country's largest manufacturer of Antibiotics,and next year it got us FDA approval

2003 Joins hands with Clinton Foundation on drugs for HIV/AIDS

2005 Third state-of-the-art R&D facility opens in Gurgaon (India)

2006 Acquires leading Romanian pharma company Terapia and Be-Tabs pharmaceuticals, 5th largest generics company in South Africa

2008 Ranbaxy partners with Daiichi Sankyo (DS) establishing a unique and powerful Hybrid Business Model; DS becomes a majority partner

2010 Ranbaxy delivers Quarterly Sales of over US $ 500 Million for the first time

2010-11The Golden Jubilee Year – 50 Years of an inspiring, pioneering and historic journey.

PRODUCT OF THE COMPANY

ACCUSPOT HIV-1/2 ACMIL ADHEB AEROMIST ALFAKIM APRELIEF ARTAGEN ASPENT AVESSA CALIBS

CALSLOT CALURAN CANDESAR-H CAPSOLA CAPSOLA PLUS CARDIBETA-AM CARDIBETA-XR CAREVON CASERA CEFDIEL

CEFDITRAN CEFTOP INJ CELIPRES CEROXIM-XP CERUVIN-A CERUVIN-AF CHLORAMSONE CIFRAN-CT-H CIFRAN-OZ CILANEM CIPROAC CLEANODERM COHERO E

CONADERM CONDERM CONTIFLO ICON CONTIFLO-D CONTIFLO-OD CORPRIL COTUSS COVANCE COVANCE-D COVANCE-D CP CROLIM OINT CROLIM POWER DARITEN-OD

DARVOCET DEXELEX DIPROBEC-S DIPROVATE PLUS DIPROVATE-N PLUS EARLIE ICON II ELIGARD ENHANCIN DPS ETROBAX EXOREX FLOTRAL FORACET FORTIRON

FORZEST FULACTIVE GENTALENE PLUS GRAMONEG-M

GRAMONEG-TN HALOX HALOX LOTION HALOX-S IMOGAM RABIES INVOZIDE KEFLEX KEFLOR-MR LEVANT

LUCI LUCI-N LULIFIN MACROGEN MEDAPINE MELUBRIN MINOZ MOBISWIFT-D MOBRINE-IR NEURONOX NIAVAS NOCULI TAB NORAZOL

OSONASE PIMERA PRASITA PRECIZE RACIPER SF RACIPER-D RACIPER-IV 40 RANBIOTIC RANODINE REFZIL-O REMICRON MR RHEOLIN RHEORAN-SF 125

RHEORAN-SF 250 RHEORAN-SF 50 RHEORAN-SF RHEOCAPS RICONIA SILVER RICONIA SYR RICONIA TAB RICONIA-G RICONIA-LP RIOMET-DUO RIOMET-G RIOMET-TRIO ROBUROL ROFIBAX

ROLES-D ROLES-SF ROLIFLO-OD ROLITEN ROLITEN-OD ROMILAST GRANUL

ES ROSCILLIN ROSUVAS SEBIFIN TAB SIMOVOTIN SIMVOTIN TAB SOLITEN SOLZAM

SOTRET SPORIDEX REDIMIX STANLIP SUDHINOL SUDOPEN SYMBIVA SYNASMA TAZOBACT TECZINE INSTAB TECZINE-AM TEVRAN

TICOVAN TOBITIL TRAMBAX TREXYDIN VEBALONE VOLIX VORZU XPHIL-NU ZANOCIN-OZ ZIVATOR

TARGET MARKET

COMPANY see each one as a its PROSPECTS

(though the products of Ranbaxy are less used by poor people because they prefer govt. hospitals for treatment, and they generally prescribe cheaper medicines to the poor people)

MARKET STRATEGY

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage. The Company has a pool of over 1,200 R&D personnel engaged in path-breaking research. 

co marketing, global approach, innovation etc are followed which are well supported by the human resource and financial practices.

SWOT ANALYSIS

Ranbaxy's Quality management system is based

on sound Quality policies and guide lines which

are implemented at all manufacturing sites all

over the world. In Ranbaxy, Quality is more than a regulatory Requirement; rather, it is a

way of life that covers product development, manufacturing, transportation and

complaint handling.

STRENGTH:

weakness

Lack of product patents

Opportunities

1,200 R&D personnel engaged this leads to long term competitive advantage.

Affordable price ,Various sizes, Easily available, Safe, Superior packaging contributes to good market share .

Threats

The pharmaceutical industry witnesses price competition which reduces the growth of the Ranbaxy in value terms.

Thank you